New hope for stomach and bowel cancers: experimental drug SKB571 enters Mid-Stage trial

NCT ID NCT07564466

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This study tests an experimental drug called SKB571 in 120 adults with gastrointestinal tumors (cancers of the stomach, intestines, or related organs). The main goal is to see if the drug shrinks tumors and to check for side effects. Participants must have measurable tumors and be in good overall health. The study is not yet recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, 250117, China

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, 404000, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, 210009, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, 3300029, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200127, China

  • Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, 030013, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, 610041, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050011, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, 530021, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710004, China

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510655, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Tumor Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150081, China

Conditions

Explore the condition pages connected to this study.